Dr King (previously O'Doherty) is a Senior Lecturer in UniSA Clinical and Health Sciences.
She contributes to Pharmacology teaching and is a Research Education Portfolio Leader (REPL).
Dr King has an interest in genetic variability and disease/treatment outcomes and is a member of the Australian Centre for Precision Health. She completed her undergraduate Master of Pharmacy Degree at Queen's University, Belfast, and her subsequent pre-registration training with Boots The Chemists, Edinburgh, as a student of the Royal Pharmaceutical Society of Great Britain. She returned to Queen's University, Belfast in 2004 to undertake a PhD examining the genetics of susceptibility to multiple sclerosis and... Read more
About me
Dr King (previously O'Doherty) is a Senior Lecturer in UniSA Clinical and Health Sciences.
She contributes to Pharmacology teaching and is a Research Education Portfolio Leader (REPL).
Dr King has an interest in genetic variability and disease/treatment outcomes and is a member of the Australian Centre for Precision Health. She completed her undergraduate Master of Pharmacy Degree at Queen's University, Belfast, and her subsequent pre-registration training with Boots The Chemists, Edinburgh, as a student of the Royal Pharmaceutical Society of Great Britain. She returned to Queen's University, Belfast in 2004 to undertake a PhD examining the genetics of susceptibility to multiple sclerosis and pharmacogenomics of interferon beta treatment in multiple sclerosis patients. As part of this CAST award studentship, Catherine also had the unique opportunity of working with her sponsor company, Biogen Idec in Cambridge, MA. She has worked with neurologists from various centres across Australia to identify genetic variations which may determine responsiveness to interferon beta treatment in MS patients. Besides MS genetics/pharmacogenomics, Dr King has worked in rheumatoid arthritis genetics/pharmacogenomics, and has an interest in mendelian randomisation.
About me
Doctor of Philosophy Queen's University of Belfast
Master of Pharmacy (with Honours) The Queen's University of Belfast
Genetics of human disease
Pharmacogenetics/Pharmacogenomics
Research
Excludes commercial-in-confidence projects.
Identification of factors that influence efficacy and toxicity with leflunomide in the treatment of rheumatoid arthritis, Arthritis Australia, 01/01/2014 - 30/09/2015
Research
Research outputs for the last seven years are shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2020 |
Open access
7
7
110
|
| 2020 |
Open access
19
23
152
|
| 2020 |
Open access
2
2
12
|
| 2017 |
2
2
|
| 2017 |
19
17
13
|
| Year | Output |
|---|---|
| 2021 |
3
3
|
| 2020 |
Open access
7
7
110
|
| 2020 |
Open access
19
23
152
|
| 2020 |
Open access
2
2
12
|
| 2017 |
2
2
|
| 2017 |
19
17
13
|
| 2015 |
Open access
8
14
|
| 2015 |
15
9
14
|
| 2014 |
6
5
1
|
| 2014 |
7
7
1
|
| 2014 |
49
46
5
|
| 2014 |
Open access
20
19
|
| 2014 |
2
2
7
|
| 2014 |
Open access
14
15
4
|
| 2013 |
Open access
14
14
|
| 2013 |
37
33
|
| 2012 |
Open access
60
54
20
|
| 2012 |
23
23
|
| 2012 |
Open access
38
35
5
|
| 2010 |
61
57
|
| 2009 |
Open access
39
36
|
| 2009 |
33
31
|
| 2008 |
30
31
|
Research
Genetics of human disease
Pharmacogenetics/Pharmacogenomics
External engagement & recognition
| Organisation | Country |
|---|---|
| Australian National Fabrication Facility Limited | AUSTRALIA |
| CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
| Flinders University | AUSTRALIA |
| Institute of Medical and Veterinary Science | AUSTRALIA |
| Johns Hopkins University | UNITED STATES |
| Johns Hopkins University School of Medicine | UNITED STATES |
| Mayo Clinic | UNITED STATES |
| National Neuroscience Institute | SINGAPORE |
| Queen Mary University of London | UNITED KINGDOM |
| Queen's University Belfast | UNITED KINGDOM |
| Queens University, Belfast | IRELAND |
| Royal Adelaide Hospital | AUSTRALIA |
| Royal Victoria Hospital, Belfast | IRELAND |
| Russian State Medical University | RUSSIAN FEDERATION |
| San Raffaele Scientific Institute | ITALY |
| St Vincent's Hospital | AUSTRALIA |
| University of Adelaide | AUSTRALIA |
| University of New South Wales | AUSTRALIA |
| University of South Australia | AUSTRALIA |
| University of the Basque Country | SPAIN |
External engagement & recognition
| Engagement/recognition | Year |
|---|---|
MemberPharmaceutical Society of Australia |
2017 |
Registered PharmacistPharmacy Board of Australia |
2017 |
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| Developing strategies to promote the use of treat to target strategies with conventional synthetic disease modifying anti-rheumatic drugs in patients with early rheumatoid arthritis | Current |
| Development of ex vivo models to predict the efficacy of disease modifying agents in rheumatoid arthritis | Current |
| Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis Patients: Optimizing Therapy and Risk Prediction | Current |
| A nutrigenomic study of folate/methionine status and oxidative stress in autistic disorder | Completed |
| Individualisation of leflunomide dosing in rheumatoid arthritis patients | Completed |
| Novel fabrication and operation of integrated silicon nanowire field effect biosensors for reliable detection of cancer prognostic biomarkers | Completed |
| Pharmacogenomics of interferon-beta treatment in Caucasian multiple sclerosis patients | Completed |
